NCT:NCT04303507
Other study identifiers:VIR20001
Acronym:COPCOV
Start date:May 2020
Completion date:May 2022 (Anticipated)
Primary completion date:May 2022 (Anticipated)
Study first submitted:March 6, 2020
Last update posted:March 11, 2020
Sponsor:University of Oxford
Collaborators:
Enrollment:10000
The study is a double-blind, randomised, placebo-controlled trial that will be conducted in health care settings. After obtaining fully informed consent, the investigator will recruit healthcare workers, or other individuals at significant risk who can be followed reliably for 5 months. 10,000 participants will be recruited and the investigator predict an average of 200 participants per site in 50 sites.
The participant will be randomised to receive either chloroquine or placebo (1:1 randomisation). A loading dose of 10mg base/kg, followed by 150 mg daily (250mg chloroquine phosphate salt) which will be taken for 3 months or until they are diagnosed with COVID-19. Subsequent episodes of symptomatic respiratory illness, including symptomatic COVID-19, clinical outcomes, and asymptomatic infection with the virus causing COVID-19 will be recorded during the follow-up period.
Categories: DPC News
